Register to chat with like-minded investors on our interactive forums.

Get Started

CBYL Kalvista Pharmaceuticals (MM)

0.6792

0.00 (0.00%)

Pre Market

Last Updated: 20:00:00

Delayed by 15 minutes

Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Vivo Ventures VI, LLC	2. Issuer Name and Ticker or Trading Symbol Carbylan Therapeutics, Inc. [ CBYL ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) C/O VIVO CAPITAL LLC, 575 HIGH STREET, SUITE 201	3. Date of Earliest Transaction (MM/DD/YYYY) 4/14/2015
(Street) PALO ALTO, CA 94301 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY) 4/14/2015	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	4/14/2015		C		2476452 ⁽²⁾	A	⁽¹⁾	2476452	I	See Footnotes ⁽²⁾ ⁽⁶⁾
Common Stock	4/14/2015		C		18140 ⁽³⁾	A	⁽¹⁾	2494592	I	See Footnotes ⁽³⁾ ⁽⁶⁾
Common Stock	4/14/2015		C		387960 ⁽²⁾	A	⁽⁴⁾	2882552	I	See Footnotes ⁽²⁾ ⁽⁶⁾
Common Stock	4/14/2015		C		2842 ⁽³⁾	A	⁽⁴⁾	2885394	I	See Footnotes ⁽³⁾ ⁽⁶⁾
Common Stock	4/14/2015		C		304438 ⁽²⁾	A	⁽⁵⁾	3189832	I	See Footnotes ⁽²⁾ ⁽⁶⁾
Common Stock	4/14/2015		C		2230 ⁽³⁾	A	⁽⁵⁾	3192062	I	See Footnotes ⁽³⁾ ⁽⁶⁾
Common Stock	4/14/2015		P		1005136 ⁽²⁾	A	$5.00	4197198	I	See Footnotes ⁽²⁾ ⁽⁶⁾
Common Stock	4/14/2015		P		7364 ⁽³⁾	A	$5.00	4204562	I	See Footnotes ⁽³⁾ ⁽⁶⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series B Convertible Preferred Stock	⁽¹⁾	4/14/2015		C			2476452	⁽¹⁾	⁽¹⁾	Common Stock	2476452	⁽¹⁾	0	I	See Footnote ⁽²⁾
Series B Convertible Preferred Stock	⁽¹⁾	4/14/2015		C			18140	⁽¹⁾	⁽¹⁾	Common Stock	18140	⁽¹⁾	0	I	See Footnote ⁽³⁾
Convertible Promissory Note	⁽⁴⁾	4/14/2015		C			387960	⁽⁴⁾	⁽⁴⁾	Common Stock	387960	⁽⁴⁾	0	I	See Footnote ⁽²⁾
Convertible Promissory Note	⁽⁴⁾	4/14/2015		C			2842	⁽⁴⁾	⁽⁴⁾	Common Stock	2842	⁽⁴⁾	0	I	See Footnote ⁽³⁾
Convertible Promissory Note	⁽⁵⁾	4/14/2015		C			304438	⁽⁵⁾	⁽⁵⁾	Common Stock	304438	⁽⁵⁾	0	I	See Footnote ⁽²⁾
Convertible Promissory Note	⁽⁵⁾	4/14/2015		C			2230	⁽⁵⁾	⁽⁵⁾	Common Stock	2230	⁽⁵⁾	0	I	See Footnote ⁽³⁾

Explanation of Responses:
( 1)	Upon the closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a one for one basis without payment or further consideration, and has no expiration date.
( 2)	The reported shares are held directly by Vivo Ventures Fund VI, L.P. ("VIF"). Vivo Ventures VI, LLC ("Vivo LLC") is the general partner of VIF. As such, Vivo LLC may be deemed to be the beneficial owner of the shares held directly by VIF. The managers of Vivo LLC include Frank Kung, Edgar Engleman, and Albert Cha. Accordingly, each Frank Kung, Edgar Engleman and Albert Cha may be deemed to be the beneficial owner of the shares held directly by VIF. Each of Vivo LLC, Frank Kung, Edgar Engleman and Albert Cha disclaims beneficial ownership of the securities held by VIF, except to the extent of such individual's or entity's pecuniary interests in the securities.
( 3)	The reported shares are held directly by Vivo Ventures VI Affiliates Fund, L.P. ("VIAF"). Vivo Ventures VI, LLC ("Vivo LLC") is the general partner of VIAF. As such, Vivo LLC may be deemed to be the beneficial owner of the shares held directly by VIAF. The managers of Vivo LLC include Frank Kung, Edgar Engleman, and Albert Cha. Accordingly, each Frank Kung, Edgar Engleman and Albert Cha may be deemed to be the beneficial owner of the shares held directly by VIAF. Each of Vivo LLC, Frank Kung, Edgar Engleman and Albert Cha disclaims beneficial ownership of the securities held by VIAF, except to the extent of such individual's or entity's pecuniary interests in the securities.
( 4)	The Convertible Promissory Note is convertible into the number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing the entire principal amount and 184 days of accrued interest on the Convertible Promissory Note by 80% of the initial public offering price of $5.00 per share of the Issuer's Common Stock, automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
( 5)	The Convertible Promissory Note is convertible into the number of shares of the Issuer's Common Stock equal to the quotient obtained by dividing the entire principal amount and 41 days of accrued interest on the Convertible Promissory Note by 80% of the initial public offering price of $5.00 per share of the Issuer's Common Stock, automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
( 6)	The number of shares in Column 5 represents the aggregate number of shares directly beneficially owned by both VIF and VIAF. Vivo LLC, the Designated Reporting Person, is the general partner of both VIF and VIAF.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Vivo Ventures VI, LLC C/O VIVO CAPITAL LLC 575 HIGH STREET, SUITE 201 PALO ALTO, CA 94301		X
Vivo Ventures Fund VI, L.P. 575 HIGH STREET, SUITE 201 PALO ALTO, CA 94301		X
VIVO VENTURES VI AFFIILATES FUND, L.P. 575 HIGH STREET, SUITE 201 PALO ALTO, CA 94301		X

Signatures
By: /s/ Albert Cha, M.D., Ph.D., Managing Member of Vivo Ventures VI, LLC, the General Partner of Vivo Ventures VI Fund L.P. and Vivo Ventures VI Affiliates Fund, L.P.		4/24/2015
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

CARBYLAN THERAPEUTICS, INC. (NASDAQ:CBYL)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more CARBYLAN THERAPEUTICS, INC. Charts.

CARBYLAN THERAPEUTICS, INC. (NASDAQ:CBYL)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more CARBYLAN THERAPEUTICS, INC. Charts.

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Share on Facebook Share on Twitter Share on Email

Loading Messages....

See More Message Board Posts

Carbylan Therapeutics, Inc. News

More Carbylan Therapeutics, Inc. News Articles

Greene Concepts (PK)

Movement Industries (PK)

Kraig Biocraft Laborator... (QB)

Therapeutic Solutions (PK)

Elite Pharmaceuticals (QB)

Mullen Automotive

Innerscope Hearing Techn... (PK)

Alternet Systems (PK)

Digital Brand Media and ... (PK)

International Star (PK)

Enzolytics (PK)

Delayed Upgrade Clock